KBY Biotech Indexv0.0.34
Search
← Pipeline|Olpaglumide

Olpaglumide

Approved
ROV-5657
By Laboratorios Rovi
Source: Trial-derived·Trials: 4
Modality
Nanobody
MOA
CGRPant
Target
KRASG12C
Pathway
JAK/STAT
EpilepsyHNSCCPsoriasis
Development Pipeline
Preclinical
~Mar 2011
→ ~Jun 2012
Phase 1
~Sep 2012
→ ~Dec 2013
Phase 2
~Mar 2014
→ ~Jun 2015
Phase 3
~Sep 2015
→ ~Dec 2016
NDA/BLA
~Mar 2017
→ ~Jun 2018
Approved
Sep 2018
→ Mar 2030
ApprovedCurrent
NCT04217569
2,544 pts·HNSCC
2025-02→2025-02·Active
NCT05258048
2,211 pts·Epilepsy
2018-09→2026-12·Terminated
NCT03100265
1,191 pts·Psoriasis
2021-10→2030-03·Recruiting
+1 more trial
7,363 total pts3 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-02-251.1y agoPh3 Readout· HNSCC
2026-03-034w agoPh3 Readout· HNSCC
2026-12-199mo awayPh3 Readout· Epilepsy
2030-03-164.0y awayPh3 Readout· Psoriasis
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Termina…
Approved
Recruit…
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2025-02-25 · 1.1y ago
HNSCC
Ph3 Readout
2026-03-03 · 4w ago
HNSCC
Ph3 Readout
2026-12-19 · 9mo away
Epilepsy
Ph3 Readout
2030-03-16 · 4.0y away
Psoriasis
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT04217569ApprovedHNSCCActive2544OS
NCT05258048ApprovedEpilepsyTerminated2211EFS
NCT03100265ApprovedPsoriasisRecruiting1191LiverFat
NCT04321420ApprovedHNSCCRecruiting1417EDSS
Competitors (10)
DrugCompanyPhaseTargetMOA
TerafutibatinibPfizerPhase 1/2CD38CGRPant
SotovorutinibPfizerApprovedAβCGRPant
JNJ-179Johnson & JohnsonApprovedKRASG12CBETi
ABB-3060AbbViePhase 2LAG-3CGRPant
BMY-4586Bristol-Myers SquibbPreclinicalKRASG12CIL-13i
DoxarapivirBristol-Myers SquibbPhase 3KRASG12CSOS1i
AMG-4531AmgenPhase 2/3KRASG12CPRMT5i
GIL-6239Gilead SciencesPhase 2TNFαCGRPant
TezecilimabRegeneronApprovedIL-23CGRPant
REG-8074RegeneronPhase 2/3KRASG12CCAR-T BCMA